Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931793 | 0.90 | POLB (0.38) | POLBPIK3CAMEN1KMT2AMAPT | |
| SCHEMBL8207645 | 0.84 | ALDH1A1 (0.35) | POLBMEN1KMT2AMAPTHTT | |
| SCHEMBL2927512 | 0.83 | CYP46A1 (0.41) | POLBPIK3CAHCRTR1HCRTR2 | |
| SCHEMBL2931509 | 0.82 | HTR2A (0.35) | POLBMEN1KMT2AMAPTHTT | |
| SCHEMBL2928729 | 0.81 | HCRTR1 (0.42) | POLBHCRTR1HCRTR2 | |
| SCHEMBL2924235 | 0.81 | POLB (0.39) | POLBPIK3CAALDH1A1HPGDHCRTR1 | |
| SCHEMBL2929940 | 0.81 | HCRTR1 (0.38) | HCRTR1HCRTR2 | |
| SCHEMBL2926153 | 0.79 | HDAC7 (0.44) | POLBHCRTR1HCRTR2 | |
| SCHEMBL2931094 | 0.79 | PIK3CA (0.36) | POLBPIK3CAHCRTR1HCRTR2 | |
| SCHEMBL2932481 | 0.79 | GRM2 (0.40) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-B1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Phamaceuticals Ltd. (CH) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016401-A1 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | HCRTR1, HCRTR2, CNR1 | POLB 2990/4885PIK3CA 2067/4885MEN1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.